Skip to content

Author

R. Cristescu

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Aug 2026

Prevalence of High Tumor Mutational Burden Among Pediatric Patients With Solid Tumors.

High tumor mutational burden (TMB-H), defined as ≥10 non-driver somatic mutations per mega base of genome sequenced (mut/Mb), and high microsatellite instability (MSI-H), which can lead to TMB-H, are both associated with response to the immunotherapy pembrolizumab. Data from the KEYNOTE-158 study demonstrated that the...

Wen-Jun Zhong, E. Dettman, Lei Zhang et al. · 0 citations
Review Sep 2026

Final results and predictive biomarkers of response and long-term outcomes with first-line pembrolizumab monotherapy in advanced renal cell carcinoma in the phase II KEYNOTE-427 study.

BACKGROUND Previous results from the single-arm, phase II KEYNOTE-427 study showed antitumor activity with first-line pembrolizumab monotherapy in advanced clear cell renal cell carcinoma (ccRCC) and non-clear cell RCC (nccRCC). We report results of the final efficacy and safety analyses and exploratory, predictive bio...

D. McDermott, S. Signoretti, J.-L. Lee et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.